Thank you for subscribing!

Helping Build Up a Vital Industry

How Patient Access Solutions is Optimizing Healthcare Practices

Patient Access Solutions, Inc. (OTC:PASO) provides technology and management solutions for the healthcare industry. They offer practices the administrative framework necessary to run a thriving, profitable healthcare business. With over 40 years of combined industry experience, PASO is well-equipped to help practitioners navigate the constantly shifting healthcare landscape. Though 2020 took a toll on everyone, PASO has bounced back better than ever in 2021, opening a new facility in Long Island, New York and acquiring, a service that allows patients to access mental health treatment remotely.

Making Mental Health Care Efficient and Accessible

Many challenges within our healthcare industry can be traced back to outdated structures. For example, 60% of the United States’ top 20 hospitals don’t offer online scheduling for their new patients, often making effective care inefficient. 

“The digitization of healthcare will likely continue to gather speed, and as hospitals and health systems look ahead, they should prioritize creating an end-to-end digital access experience,” reads News & World Report’s 2020-21 Best Hospitals report. 

It’s problems like these that Patient Access Solutions looks to address directly, with their acquisition of and partnership with Veterans for America First. The partnership has rolled out a service to provide 24/7 mental health visits for veterans at a low monthly membership rate and no co-pay. Patients are given supportive counseling, 100% follow up with dedicated counselors, crisis support, and coverage for the entire family up to seven people. This program alone extends new virtual mental healthcare options to a national network of almost 400,000 veterans alone and can serve as an example of solutions that could change the entire healthcare industry when executed.

Update: Patient Access Solutions, Hestia Insight, and US Stem Cell to Form Business Consortium

COMMACK, NY (GLOBE NEWSWIRE) —  via NewMediaWire — Patient Access Solutions, Inc. (OTC: PASO), a provider of technology and management solutions for the healthcare and financial industries, has announced today that Patient Access Solutions, (PASO) Hestia Insight through its subsidiary Hestia Health, and US Stem Cell will form a Consortium business model for the treatment of individuals with anxiety and depression. 

Anxiety disorders affect 40 million adults and one in eight children in the United States. They interfere with daily functioning and often lead to depression, substance abuse, suicide attempts and other disorders. Depressive disorders affect about 19 million American adults. More than 50 percent of people diagnosed with depression also have an anxiety disorder. Coexisting anxiety and depression account for the most disabling mental health disorders in the United States.

We are coming out of a difficult period, with the COVID-19 pandemic, and we believe there are many innovative technologies that should be introduced in the healthcare industry and commercialized. Using Trancranial Magnetic Stimulation (TMS) will optimize the brain function. In recent years, the team has demonstrated that the results from treatment can lead to remarkable clinical improvements in many neuropsychiatric disorders.   

Hestia Health, US Stem Cell, and Patient Access Solutions will provide the facility locations and all business narratives including funding/financing, branding, patient awareness campaigns, licensing, facility build outs, and billing.

The global healthcare market reached a value of nearly $8,452 billion in 2018, having grown at a compound annual growth rate (CAGR) of 7.3% since 2014, and is expected to grow at a CAGR of 8.9% to nearly $11,909 billion by 2022

About Patient Access Solutions Inc.(

More About Patient Access Solutions here.

EMBP: Effective Treatments for Complex Mental Health Challenges

The National Alliance on Mental Illness estimates 1 in 5 adults experience some form of mental health issue in 2020. Of those adults, 14.2 million (approximately 1 in 20) suffer from severe mental health disorders — debilitating afflictions like severe post traumatic stress disorder, major depressive disorder, or similar illnesses that can have social, physical, and financial impacts on life. These ripple effects have been linked to the 17 million American adults with a mental illness who experience a substance abuse disorder, or the higher rate of unemployment among adults with mental illnesses.

All this is to say mental health is a significant segment of our healthcare system worthy of finding proven, beneficial treatments. From a market perspective, mental health treatment is projected to surpass $537B by 2030, growing at a CAGR of 3.5%.

Better Life Clinics, a Patients Access Solutions subsidiary, is addressing mental health treatment with one of the most groundbreaking techniques in the industry: Electromagnetic Brain Pulse, or EMBP. EMBP is designed to restore the brain’s normal function, as in the optimized brain activity that would occur without the disruption of a mental illness. It’s a non-invasive, physician-led procedure in which brain patterns and activity are recorded. This helps the physician develop customized Transcranial Magnetic Stimulation, stimulating the brain’s nerve cells with electromagnetic pulses.

Primary treatments last approximately a month, following consultations and trials that are spread out over several days. Effective treatments result in a range of improved outcomes, from improved sleep to reduced anxiety, greater emotional stability, and more, dependent on the disorder being treated.

The video below offers detailed testimonials of patients who have benefited from this breakthrough treatment, sharing their symptoms before EMBP treatment, the positive changes they’ve experienced as a result, and more from their personal stories. 

Throw A Lasso Over PASO

New Field of Practice Adds Value – The PASO Clinics will be revolutionizing “Non-Pharma” therapies for mental health disorders, by aggregating “Best of Breed” new therapies. These therapies are also gaining momentum in the billing/reimbursement area of practice management, which PASO is at the forefront of. 

Experienced Team – The management team has over 40 years combined experience, helping optimize health practices. 

Good Projections – As PASO rolls out their care facilities, they are projecting revenues of approx. $5M in 2021 and $9M by 2022, with costs of $1M and $3M respectively. 

Growing Markets – The healthcare market is expected to grow at a CAGR of 8.9%, while the patient access solutions market is expected to grow at a CAGR of 8%. As both markets expand, PASO is well positioned to ride the wave. 

A Needed Service – The administrative and managerial services PASO provides increase the profitability and efficiency of their partners. 

Providing a Solid Framework for the Healthcare Industry

Patient Access Solutions Inc. (OTC: PASO) is positioned for growth. Their administrative and managerial services, from billing solutions to revenue cycle management, are critical to meeting the needs of a rapidly evolving health care marketplace. Using an arsenal of technology, resources, and partnerships, PASO maximizes productivity and profitability across a broad range of health care businesses. 

Recently, PASO opened and has begun managing a new medical facility in Long Island, NY through their management group, PASHealth Management.. The unique approach of his facility is unlike any other, offering state of the art Biological Mental Health solutions, designed to help diagnose and treat anxiety, depression, PTSD, and more. The structure and guidance that PASO provides will be key in the growth and success of this new facility, where they will be offering Brain Mapping, Transcranial Magnetic Stimulation, an IV Suite, and more. 

The opening of this Long Island facility has been exciting, as PASO is projecting revenues of $3M-$5M in the first year, with more facilities to follow. Beyond the financial upside though, is tackling the very real issue of anxiety and depression. PASO is forming a consortium with Hestia Insights and US Stem Cell, in order to help the 40M adults who struggle with depression, anxiety, or some combination thereof. Coming out of the Covid-19 pandemic, it’s unclear how much mental health has been affected by extended lock-downs. There is clearly a population in need, and PASO will be capitalizing on the opportunity to help. 

At the end of 2021, PASO also released their CAMEO™ program. Designed to help relieve the overwhelming pressure being experienced within the mental healthcare industry, CAMEO™ is an acronym that stands for Comprehensive, Affordable, Mental Health, Effective, Outcomes.

The program is run out of the CAMEO™ New Horizons Center located in New Hyde Park, NY and provides those in need with one-on-one in-person counseling, for anxiety, stress, and depression. In addition to traditional counseling services, the New Horizons Center also offers ​​treatment protocols like Trans Cranial Magnetic Stimulation (TMS) and Ketamine Infusion therapy. On top of that, the CAMEO™ solution also offers MY BOOST IV, a unique type of therapy that can be tailored to the needs of each individual to help support overall wellbeing and to help patients live happier, healthier lives.

Recent Press Releases


Investment Considerations

New Facilities – The string of Mental Health Care facilities PASO is planning looks impressive, and the revenue potential is solid. Serving mental health is one of the ways we think businesses will see growth following the pandemic. 

Steady Hands – PASO’s leadership has 40 years combined experience, which means they’ve been through their share of ups and downs. Coming out of 2020, we’re backing teams with enough experience to turn a down into an up. 

Ready to DisruptIt’s no secret that the health care system could use some elbow grease. PASO’s bread-and-butter is the use of technology to increase efficiency and efficacy in the industry. As they continue to expand into areas like mental health, with strong partners like Hestia and US Stem cell, they are positioned to be a truly disruptive force in a market that needs it. 

Many Americans want to see their healthcare industry undergo massive reform, with 63% of adults saying the U.S. Government should be providing coverage for all. The fact is that does not exist today, with a growing demand for care that’s both reliable and affordable. And while the demand for care will not diminish, the demand for mental health care is growing significantly. 

Patient Access Solutions’ partnership with and Veterans for America first may lay the foundation that grants accessible mental health care to more Americans. Hourlong therapy sessions can range from $65 to well over $200 per hour for those without insurance. But even those with insurance can face significant costs, with patients diagnosed with depression, for example, spending more than $10,000 per year for care. 

The verdict: mental health care is neither affordable nor accessible for many. Patient Access Solutions is addressing that public need directly. And as more Americans create demand for affordable care, subscription-based services that don’t drain pockets such as the one introduced by Patient Access Solutions have the potential to lead us toward the reform many want.


Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Patient Access Solutions, Inc. (PASO)
  • Amount & Form of Compensation - $1,500,000 in Common Stock
  • Who Paid for the Campaign & Position with Company if any - Patient Access Solutions, Inc. (PASO)
  • Period of Campaign - 4/12/2021-4/12/2022
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Patient Access Solutions, Inc. (PASO)
  • Number of Shares We or our Affiliates Hold - 125,000,000
  • Price We Paid Per Share - $0
  • Date Issued - 3/22/2021

Related Post

Register to Learn More

Go to website
Go to top